Encorafenib (LGX818) is a Potent BRAF Inhibitor for Melanoma Cancer Research
Melanoma is an immunologic malignancy characterized by higher prevalence in immune-compromised patients. In addition, once melanoma has spread, this type of cancer rapidly becomes life-threatening. Moreover, Melanoma is the ninth most common malignancy and the second for mortality. According to the statistics, cutaneous melanoma causes 55 500 deaths annually....